WFL 0.00% 0.3¢ wellfully limited

us patent granted, page-88

  1. 5,330 Posts.
    lightbulb Created with Sketch. 32
    Hi MG

    "I still think there's the possibility that negative info could be hidden by the company"

    When all programs are tied up in confidentiality agreements I'd say we can almost be guaranteed that the company is hiding a lot more positive news.

    "I think Surges said "it's a done deal" if I remember rightly, so it would be interesting to see what he now thinks if you see it differently."

    Based on the strong long term relationship OBJ already have established with GSK along with expanded programs and extremely encouraging study results reported why would I think any different to a most respected and researched poster?

    My counter argument with you was only in response to your comment, "GSK's statement that they are making products with OBJ beats all the research posted here."

    You have often accused posters of putting a positive spin on everything or too much ramping yet your own comment, "GSK's statement that they are making products with OBJ..." could be considered as misleading, especially when coming from a poster like yourself who emphasizes the importance of balance - fair enough?

    I'm happy to admit that I often post with a lot of optimism and confidence for the future of this company but I also make the conscious effort to provide some substance behind my enthusiasm.
    ___

    I'll leave you with some words from the MD of SR1, Mr David Phillips. SR1 is GlaxoSmithKline's corporate venture capital arm and in this interview Mr Phillips talks to Mr Marc Dresner from the Drug Delivery Partnerships conference.

    No sensitive information disclosed of course but when one thinks outside the box here it helps to better understand the strength, determination and hunger for success shown by one of our collaborating partners.

    "Phillips explains how SR1's goal is to stay ahead of the innovation game by investing in companies who have begun creating the advanced technology his company is looking for, both now and in the future. He also comments that they look for new ways to develop existing technologies in ways they're not using them."

    enjoy...

    Drug Delivery Partnerships TV: An Interview with David Phillips
 
watchlist Created with Sketch. Add WFL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.